Raymond James & Associates Exelixis, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Exelixis, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 239,661 shares of EXEL stock, worth $8.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

239,661

Previous 109,856 118.16%

Holding current value

$8.58 Million

Previous $2.47 Million 151.99%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$21.96 - $27.6 $2.85 Million - $3.58 Million	129,805 Added 118.16%	239,661 $6.22 Million
Q2 2024 Jul 19, 2024	BUY	$20.34 - $23.73 $27,011 - $31,513	1,328 Added 1.22%	109,856 $2.47 Million
Q1 2024 Apr 22, 2024	SELL	$20.17 - $23.93 $102,927 - $122,114	-5,103 Reduced 4.49%	108,528 $2.58 Million
Q4 2023 Jan 16, 2024	BUY	$19.25 - $24.13 $80,561 - $100,984	4,185 Added 3.82%	113,631 $2.73 Million
Q3 2023 Oct 24, 2023	SELL	$19.04 - $22.74 $545,553 - $651,569	-28,653 Reduced 20.75%	109,446 $2.39 Million
Q2 2023 Jul 25, 2023	SELL	$18.17 - $20.48 $245,458 - $276,664	-13,509 Reduced 8.91%	138,099 $2.64 Million
Q1 2023 Apr 14, 2023	BUY	$16.3 - $19.41 $191,052 - $227,504	11,721 Added 8.38%	151,608 $2.94 Million
Q4 2022 Feb 08, 2023	SELL	$14.96 - $17.39 $37,519 - $43,614	-2,508 Reduced 1.76%	139,887 $2.24 Million
Q3 2022 Oct 25, 2022	BUY	$15.68 - $22.27 $920,949 - $1.31 Million	58,734 Added 70.2%	142,395 $2.23 Million
Q2 2022 Aug 12, 2022	SELL	$17.44 - $23.16 $261,024 - $346,635	-14,967 Reduced 15.18%	83,661 $1.74 Million
Q1 2022 May 11, 2022	BUY	$17.03 - $22.67 $103,951 - $138,377	6,104 Added 6.6%	98,628 $2.24 Million
Q4 2021 Feb 08, 2022	SELL	$15.84 - $21.88 $163,722 - $226,151	-10,336 Reduced 10.05%	92,524 $1.69 Million
Q3 2021 Nov 02, 2021	BUY	$16.3 - $21.14 $921,145 - $1.19 Million	56,512 Added 121.93%	102,860 $2.17 Million
Q2 2021 Aug 11, 2021	SELL	$17.95 - $25.56 $14,377 - $20,473	-801 Reduced 1.7%	46,348 $844,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $34,059 - $41,839	-1,659 Reduced 3.4%	47,149 $1.07 Million
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $16,808 - $22,667	914 Added 1.91%	48,808 $980,000
Q3 2020 Nov 04, 2020	SELL	$20.67 - $26.94 $51,364 - $66,945	-2,485 Reduced 4.93%	47,894 $1.17 Million
Q2 2020 Jul 28, 2020	BUY	$16.46 - $27.42 $104,422 - $173,952	6,344 Added 14.41%	50,379 $1.2 Million
Q1 2020 Apr 21, 2020	SELL	$14.46 - $21.8 $1.05 Million - $1.58 Million	-72,347 Reduced 62.16%	44,035 $758,000
Q4 2019 Feb 12, 2020	SELL	$15.15 - $18.89 $41,692 - $51,985	-2,752 Reduced 2.31%	116,382 $2.05 Million
Q3 2019 Nov 07, 2019	SELL	$17.68 - $22.65 $523,858 - $671,119	-29,630 Reduced 19.92%	119,134 $2.11 Million
Q2 2019 Aug 06, 2019	SELL	$18.93 - $24.75 $3.75 Million - $4.9 Million	-197,851 Reduced 57.08%	148,764 $3.18 Million
Q1 2019 May 06, 2019	BUY	$19.6 - $24.76 $1.94 Million - $2.46 Million	99,163 Added 40.07%	346,615 $8.25 Million
Q4 2018 Feb 11, 2019	SELL	$13.65 - $21.8 $40,499 - $64,680	-2,967 Reduced 1.18%	247,452 $4.87 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $2.75 Million - $3.88 Million	173,104 Added 223.89%	250,419 $4.44 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $532,931 - $644,629	28,714 Added 59.08%	77,315 $1.66 Million
Q1 2018 May 14, 2018	SELL	$22.15 - $31.89 $699,851 - $1.01 Million	-31,596 Reduced 39.4%	48,601 $1.08 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $1.25 Million - $1.59 Million	51,431 Added 178.79%	80,197 $2.44 Million
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $671,686 - $841,117	28,766	28,766 $697,000

Others Institutions Holding EXEL

# of Institutions

465

Shares Held

240M

Call Options Held

1.87M

Put Options Held

1.12M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Exelixis, Inc. Transaction History